Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI)
Guy Young(Children's Hospital of Los Angeles), Savita Rangarajan(Guy's and St Thomas' NHS Foundation Trust), Runhui Wu(Capital Medical University), Shauna Andersson(AVEO Oncology (United States)), Stacey Poloskey(Sanofi (United States)), Alok Srivastava(M.J.P. Rohilkhand University), Cecil Ross(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Salim Kichou(Sanofi (France)), Jameela Sathar(Englewood Hospital and Medical Center), Kaan Kavaklı(Ege University), Huyen Tran(The Alfred Hospital), Jing Sun(Qiqihar University), Baisong Mei(Sanofi (United States)), Zhiying Qui(Sanofi (United States))
Cited by 16
Related Papers
Genome sequence and genetic diversity of the common carp, Cyprinus carpio
|Nature Genetics|2014|677
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
|New England Journal of Medicine|2016|494
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
|The Lancet Haematology|2019|329